GeoVax Labs, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 9, 2022. GeoVax is a clinical-stage biotechnology company with no product sales to date. Its clinical programs include GEO-CM04S1 for COVID-19 and Gedeptin for head and neck cancer; other vaccine and immunotherapy programs remain preclinical or exploratory.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Grant and collaboration revenue | $385,501 | $1,823,658 |
| Research and development expense | $15,554,171 | $2,444,459 |
| General and administrative expense | $3,577,153 | $2,196,014 |
| Net loss | $18,570,317 | $2,958,068 |
| Net loss per share | $3.04 | $2.14 |
| Cash and cash equivalents at year-end | $11,423,870 | $9,883,796 |
| Working capital at year-end | $6,193,756 | $9,424,839 |
| Operating cash used | $11,196,420 | $2,750,570 |
Revenue is grant and collaboration funding, not product revenue. Profit margins are not meaningful given the absence of product sales and continuing losses. Operating cash outflow increased substantially. Financing provided $12.8 million in 2021, primarily from a public offering and warrant exercises. The GRA note was repaid and the PPP loan was forgiven; no debt was reported at December 31, 2021. Total liabilities were $7.4 million, including $5.0 million in accrued license fees, and stockholders’ equity was $4.4 million.
Changes and notable items
- Net loss widened by $15.6 million year over year. R&D expense rose $13.1 million, principally reflecting license-related costs: $5.0 million paid and $5.0 million payable under the City of Hope license, plus clinical-trial and patent reimbursements; Gedeptin license costs also contributed. G&A increased 63%.
- Grant and collaboration revenue declined 79%, mainly because Lassa grant activity and malaria collaboration revenue were lower; $81,526 in approved grant funds remained available for 2022.
- GeoVax obtained exclusive rights to GEO-CM04S1 in November 2021 and Gedeptin in September 2021. GEO-CM04S1 was in Phase 2 studies, and the Gedeptin Phase 1/2 head and neck cancer trial was enrolling.
- In January 2022, the company completed a private placement with approximately $9.2 million in net proceeds. Management said year-end cash was expected to fund planned operations into the second quarter of 2023; further financing is needed to advance programs and continue operations.
Outlook, risks, and controls
Management expects continued operating losses, negative operating cash flows, and higher R&D and G&A costs as clinical programs advance. It gave no specific revenue, earnings, or trial-completion guidance. The cash-runway estimate is subject to uncertainty; the company may need additional equity, debt, grants, or partnership funding, and financing may not be available on acceptable terms.
Key risks include clinical and regulatory failure or delay, competition, dependence on third-party manufacturers and research partners, and the need for substantial additional capital. The company also faces potential dilution from future financing and outstanding warrants. The COH license includes further scheduled payments, contingent milestones, and royalties; Gedeptin has milestone and royalty obligations.
Management concluded disclosure controls were effective, but reported a material weakness in internal control over financial reporting related to interpretation of a non-routine transaction, and said it was implementing a more comprehensive review process. The auditor issued an unqualified opinion on the financial statements but did not audit or opine on internal-control effectiveness. No material legal proceedings were reported.
Important facts for investors to verify
- Whether subsequent financing is sufficient to extend the stated runway and fund planned clinical development.
- Clinical-trial enrollment, safety, immunogenicity, and efficacy updates for GEO-CM04S1 and Gedeptin.
- Progress in remediating the material weakness and whether controls operate effectively in later reporting periods.
- Timing and funding of City of Hope license payments, other license commitments, and potential milestone or royalty obligations.
- Potential dilution from outstanding and subsequently issued warrants, options, and future capital raises.